Tocagen (Replicating Gene Therapy Platform and Related Assets) is Buildings and Property in United States that focus on related assets business. They cover business area such as a portfolio, asset, gene therapy platform, an innovative approach, RRV, a prodrug, cancer cell, a tumor, minimal toxicity.
-
Related Assets
-
4242 Campus Point Court
Suite 600
San Diego, CA 92121
United States
Private
a portfolioassetgene therapy platforman innovative approachRRVa prodrugcancer cella tumorminimal toxicity
* We use standard office opening hours in near Tocagen (Replicating Gene Therapy Platform and Related Assets)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Tocagen (Replicating Gene Therapy Platform And Related Assets) is Buildings and Property business from United States that founded in - ( years old in ), Tocagen (Replicating Gene Therapy Platform and Related Assets) business is focusing on Related Assets.
Tocagen (Replicating Gene Therapy Platform and Related Assets) headquarter office and corporate office address is located in 4242 Campus Point Court Suite 600 San Diego, CA 92121 United States.
Tocagen (Replicating Gene Therapy Platform and Related Assets) was founded in United States.
In , Tocagen (Replicating Gene Therapy Platform and Related Assets) is currently focus on related assets sector.
Above is snippet of Google Trends for "related assets" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Tocagen (Replicating Gene Therapy Platform and Related Assets), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
